Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025

Course Name (Course Code): DRUG DESIGN (MBT20406A)

Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)

DRUG DESIGN (MBT20406A)

Study Material: Module 1
Introduction to Drug Design and Lead Discovery
Table of Contents

Sl. No. Contents Page #

1.8 Target Identification and Validation 2-3
1.9 Drug Discovery Pipeline 3-5
1.10 Random Screening and High-Throughput Screening (HTS) 5-6
1.11 Non-Random Screening Approaches 6
1.12 Traditional Medicine–Based Leads (Ethnopharmacological Approach) 6-7
1.13 Serendipitous Discovery and Clinical Observations 7-9
1.14 Lead Discovery Based on Drug Metabolism Studies. 9-10
1.15 Rational Approaches to Lead Discovery 11-12
1.16 Model Questions

1
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
1.8 Target Identification and Validation
A drug discovery programme initiates because there is a disease or clinical condition without suitable
medical products available and it is this unmet clinical need which is the underlying driving motivation
for the project. The initial research, often occurring in academia, generates data to develop a
hypothesis that the inhibition or activation of a protein or pathway will result in a therapeutic effect
in a disease state. The outcome of this activity is the selection of a target which may require further
validation prior to progression into the lead discovery phase in order to justify a drug discovery effort.
During lead discovery, an intensive search ensues to find a drug-like small molecule or biological
therapeutic, typically termed a development candidate, that will progress into preclinical, and if
successful, into clinical development and ultimately be a marketed medicine.

Target Identification
A target is defined as a biological entity, such as a gene, protein, or RNA, that plays a significant role
in a disease state. The primary goal of target identification is to find a "druggable" candidate—one
that is accessible to drug molecules and elicits a measurable biological response both in vitro and in
vivo. Modern identification relies heavily on data mining, a bioinformatics approach that analyzes vast
sources of information, including clinical research, patents, proteomics, and gene expression data, to
prioritize potential disease targets.
One common approach involves examining mRNA and protein levels to determine if their expression
correlates with disease progression or exacerbation. Furthermore, researchers look for genetic
associations, such as polymorphisms or mutations that link specific genes to disease risk. For example,
mutations in amyloid precursor proteins are linked to Alzheimer's Disease, while specific sodium
channel mutations determine pain sensitivity. Another powerful method is phenotypic screening,
where researchers might use phage-display antibody libraries to identify unique antigens highly
expressed on malignant cells.
In rational drug design, identifying specific chemical responses in the body allows scientists to tailor
treatments to a specific treatment profile. Once a target is identified, it must meet rigorous criteria: it
must be efficacious, safe, and satisfy both clinical and commercial objectives. Understanding the
nature of the target, such as whether it is a G-protein-coupled receptor (GPCR) or an enzyme, helps
determine if it is more amenable to small molecule drugs or biological therapeutics like antibodies.
This stage marks the beginning of the drug discovery process.

Target Validation
Target validation is the process of proving that the inhibition or activation of a chosen target will result
in a therapeutic effect while remaining safe. Because drugs often fail due to a lack of efficacy or safety
issues, validation is critical for increasing confidence in the relationship between a target and a
disease. Researchers typically use a multi-validation approach involving in vitro secondary assays, cell-
based models, and whole-animal models.
Several genetic tools are utilized for this purpose. Antisense technology uses chemically modified
oligonucleotides to bind to target mRNA, blocking the synthesis of specific proteins; this method is
advantageous because its effects are reversible. Similarly, small interfering RNA (siRNA) utilizes the
RNAi pathway to induce mRNA cleavage and silence gene expression. Transgenic animals, such as gene
knockouts or knock-ins, provide essential insights by allowing scientists to observe the functional
consequences of gene manipulation in a living organism. For example, P2X7 knockout mice were used
to confirm that specific ion channels play an unambiguous role in inflammatory pain.
Biological and chemical tools also play a major role. Monoclonal antibodies (mAbs) are excellent
validation tools due to their high affinity and specificity for unique epitopes, which minimizes "off-
target" toxicity, though they are generally limited to cell-surface or secreted proteins. Furthermore,
2
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
chemical genomics involves the systematic use of small tool molecules to study genomic responses
and evaluate cellular function before committing to a full screening campaign. Ultimately, target
validation must demonstrate that the target is effective, safe, and "drug-like" to justify the high costs
and effort of further drug development. Successful validation allows researchers to transition into the
lead discovery phase with greater assurance.

1.9 Drug Discovery Pipeline:

Target identification & validation → Hit discovery → Lead discovery → Lead optimization → Preclinical
studies

Following target validation, where genetic, cellular, and in vivo experimental models are used to
confirm the relevance of a biological target to disease, large compound libraries are evaluated during
compound screening. At this stage, high-throughput and selective screening approaches identify hits,
which are compounds that exhibit measurable biological activity against the target but may lack
optimal potency, selectivity, or drug-like properties. These hits then undergo hit-to-lead development
during the secondary assay phase, where in vitro and ex vivo mechanistic assays, along with selectivity
and liability testing, are employed to confirm activity and eliminate false positives. Through iterative
chemical modification and structure–activity relationship studies, promising compounds are refined
into leads with improved potency and pharmacological profiles. The optimized leads are subsequently
evaluated in in vivo analysis using disease efficacy models, pharmacokinetic studies, and early safety
and toxicity assessments. Finally, the most suitable optimized lead progresses as a preclinical
candidate, entering comprehensive safety and toxicity testing prior to clinical development.

3
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)

Methods of Lead Discovery

Lead discovery is the process of identifying chemical compounds (leads) that show sufficient biological
activity and selectivity against a validated target and are suitable for further optimization.
Before a lead is identified, compounds are first detected as hits through screening approaches. These
hits are then refined and optimized to generate leads.
A lead nucleus is identified by screening a series of compounds for a specific biological activity. Once
identified, the structure of the lead is chemically modified to improve potency, selectivity, and safety.

Activity vs Potency
• Activity: The type of pharmacological effect produced (e.g., antihypertensive, anticancer).
• Potency: The amount (dose or concentration) required to produce that effect.

Important Methods of Lead Identification

1. Random Screening
• Large numbers of compounds are tested without prior knowledge of target or mechanism.
• Can involve natural products, synthetic libraries, or existing chemical collections.
• Advantage: May discover novel scaffolds.
• Limitation: Time-consuming, expensive, low success rate.
2. Non-Random (Target-Based) Screening
• Compounds are selected based on known biological targets or disease pathways.
• Uses in vitro assays, enzyme inhibition studies, receptor binding assays.
• More efficient and hypothesis-driven compared to random screening.
3. Drug Metabolism Studies
• Metabolites of known drugs may show improved activity or reduced toxicity.
• Some metabolites themselves become leads.
• Example: Active metabolites with better bioavailability than parent drug.
4. Clinical Observations
• Leads identified from unexpected therapeutic effects seen during clinical use.
• Also known as serendipitous discovery.
4
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
• Example: Sildenafil originally developed for angina, later used for erectile dysfunction.
5. Rational Approaches to Lead Discovery
• Based on knowledge of target structure, ligand–receptor interactions, and SAR.
• Includes:
o Structure-based drug design
o Ligand-based drug design
o Pharmacophore modeling
• Highly efficient and widely used in modern drug discovery.

1.10 Random Screening and High-Throughput Screening (HTS)

Random Screening Method of Lead Discovery
The random screening method is a foundational, empirical approach to lead discovery in which a large
number of compounds are tested without prior knowledge of their biological target or mechanism of
action. All available compounds in a given series—including synthetic chemicals and natural products
of plant, marine, and microbial origin—are evaluated for a desired biological activity. Because
compound selection is not guided by a predefined hypothesis, this approach is considered unbiased,
stochastic, and chance-based.
Historically, random screening has played a pivotal role in drug discovery and has led to the
identification of numerous first-in-class drugs. Classical examples include morphine, cocaine, digitalis,
nicotine, muscarine, tubocurarine, and quinine, which were discovered through empirical testing of
natural substances. More recent successes include the anticancer agent taxol and the antimalarial
drug artemisinin from plant sources. Similarly, antibiotics such as streptomycin and tetracyclines,
fungal metabolites like lovastatin and cyclosporine, and the potent marine-derived anticancer
compound euracin A demonstrate the effectiveness of this approach across diverse biological sources.
Traditionally, random screening relied on a manual “trial-and-error” strategy, where compounds from
varied sources were tested against multiple biological systems. Although this method was highly
productive—particularly for natural product discovery—it suffered from a low probability of success,
with only about 1 in 10,000 compounds progressing as a viable lead. Despite being resource-intensive
in terms of time, cost, and manpower, random screening remains valuable because it can uncover
unexpected biological activities and novel chemical scaffolds that may not be predicted by rational or
target-based approaches.

High-Throughput Screening (HTS): Modern Extension of Random Screening

In modern drug discovery, random screening has evolved into High-Throughput Screening (HTS), a
technology-driven approach that enables the rapid identification of hits from very large chemical
libraries. HTS uses automation, robotics, liquid-handling systems, sensitive detection technologies,
and data-processing software to screen hundreds of thousands to millions of compounds efficiently.
Compounds are stored in large chemical libraries, typically as liquid solutions in DMSO, and are
transferred robotically from stock plates into miniaturized assay plates, commonly in 384- or 1536-
well formats. Biological responses are measured rapidly, and the resulting data are stored in relational
databases linking chemical structures to biological activity.
HTS employs two main types of bioassays:
• Biochemical assays, which use isolated enzymes or proteins and offer high reproducibility with
low variability.
• Cell-based assays, which use living cells and provide more physiologically relevant
information, particularly for receptors, ion channels, and signaling pathways.

5
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
Because HTS involves massive data generation, quality control is critical. The robustness of assays is
commonly assessed using the Z′-factor, with values above 0.4 considered acceptable and values above
0.6 preferred. Preliminary training sets are often screened to validate assay performance, and heat-
map analysis is used to detect systematic errors such as edge effects or dispensing faults.

From Hits to Leads

Identification of a hit represents only the initial step. Following HTS, hits undergo a triage process in
which false positives and non-specific “frequent hitters” are eliminated. Remaining compounds are
clustered based on chemical structure, and dose–response studies are performed to determine
potency (IC₅₀ values). The most promising and selective scaffolds are then advanced to lead
optimization, where medicinal chemists improve potency, selectivity, pharmacokinetic properties,
and safety.

In summary, random screening—supported by modern HTS technologies—remains a cornerstone of

lead discovery. Although less efficient than rational and target-based approaches, it has been
instrumental in discovering many clinically important drugs and continues to be particularly valuable
for identifying novel leads from chemically diverse natural sources.

1.11. Non-Random Screening Approaches

Non-random screening approaches refer to knowledge-driven methods of lead discovery in which
compounds are selected for testing based on prior understanding of disease biology, molecular
targets, or chemical structure–activity relationships, rather than being screened blindly. Unlike
random screening, this approach is hypothesis-based and aims to improve efficiency by focusing on
compounds with a higher probability of success.
In non-random screening, the biological target is usually known and validated before screening begins.
Compounds are chosen based on their predicted ability to interact with the target, such as enzymes,
receptors, ion channels, or transporters involved in disease pathways. Screening is typically performed
using in vitro biochemical assays, receptor binding studies, or cell-based functional assays, allowing
direct measurement of target modulation.
This approach often incorporates rational drug design principles, including structure–activity
relationship (SAR) analysis, ligand-based screening, and structure-based screening when the three-
dimensional structure of the target is available. Virtual screening and computational modeling may
also be used to prioritize compounds before experimental testing, reducing time, cost, and resource
consumption.
The major advantages of non-random screening include higher hit rates, better selectivity, reduced
attrition, and a clearer understanding of mechanism of action. However, its success depends heavily
on the quality of target validation and existing biological knowledge. Incorrect target selection or
incomplete understanding of disease mechanisms can still lead to clinical failure.
Overall, non-random screening represents a more efficient and rational alternative to empirical
random screening, forming a central strategy in modern drug discovery for identifying biologically
relevant and mechanistically well-defined lead compounds.

1.12. Traditional Medicine–Based Leads (Ethnopharmacological Approach)

Traditional medicine–based leads refer to bioactive compounds or formulations derived from long-
established systems of medicine such as Ayurveda, Siddha, Unani, Traditional Chinese Medicine
(TCM), Homeopathy, and folk medicine, which serve as starting points in modern drug discovery. This
approach is considered a non-random (knowledge-based or empirical) method of lead discovery, as
the selection of sources is guided by historical therapeutic use, ethnopharmacological knowledge, and
6
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
documented clinical observations, rather than arbitrary screening. In some drug discovery
frameworks, it is also viewed as a subset of clinical observation–based lead discovery, since centuries
of human use provide indirect evidence of efficacy and tolerability.
The ethnopharmacological approach involves the systematic and multidisciplinary scientific
investigation of substances that have been traditionally used to treat diseases. These leads are
obtained from diverse natural sources, including plants, animals, microbes, marine organisms, and
inorganic materials such as minerals and metals. Traditional remedies often employ whole plants or
crude extracts, which may produce therapeutic effects through synergistic or polypharmacological
actions of multiple constituents. Modern medicinal chemistry, however, focuses on isolating,
characterizing, and optimizing the most active constituent(s) to improve potency, selectivity, and
safety while minimizing side effects associated with crude preparations.
Several major traditional medical systems have significantly contributed to lead discovery. Ayurveda,
originating in India, is based on the balance of the three doshas—Vata, Pitta, and Kapha—derived
from the five fundamental elements, with disease viewed as a disruption of this balance. Siddha
medicine, native to South India, emphasizes longevity and uses plant-based drugs along with
detoxified metals such as gold, silver, and mercury. Unani medicine, or Graeco-Arab medicine, is
founded on the equilibrium of four humours and refined physiological principles described by scholars
like Avicenna. Homeopathy, developed by Samuel Hahnemann, follows the principle of “like cures
like” and uses highly diluted natural substances to stimulate the body’s healing mechanisms.
Traditional medicine has been a rich source of historically and clinically successful drugs. Classical
examples include morphine and quinine, discovered through empirical use of natural substances.
Modern successes include artemisinin, derived from Artemisia annua used in TCM for malaria; aspirin,
originating from salicin found in willow bark; reserpine from Rauwolfia serpentina used in Ayurveda
for hypertension; and taxol, a potent anticancer agent derived from plant sources. Additional leads
have contributed to the development of anti-inflammatory agents (Curcuma longa), hypolipidaemic
drugs (Commiphora species), and hepatoprotective compounds.
Overall, traditional medicine–based lead discovery provides a chemically diverse and biologically
validated reservoir of lead compounds. By building on remedies that have already demonstrated
therapeutic benefit in humans over long periods, this approach helps reduce attrition rates, narrows
the search space for new drugs, and continues to play a vital role in modern medicinal chemistry and
drug development.

1.13. Serendipitous Discovery and Clinical Observations in Lead Identification

Serendipitous discovery and clinical observations represent empirical, non-rational approaches to lead
identification in drug discovery. Unlike rational or target-based strategies, these methods do not begin
with a predefined molecular target or hypothesis. Instead, they rely on careful observation, chance
findings, and the scientific insight (sagacity) of researchers or clinicians to recognize unexpected
therapeutic effects. Such discoveries are later subjected to retrospective scientific validation, including
mechanistic, pharmacological, and toxicological studies.

Serendipitous Discovery
The term serendipity originates from the Persian fairy tale The Three Princes of Serendip, in which
discoveries were made through “accidents and sagacity.” In drug discovery, serendipitous discovery
refers to the identification of a useful therapeutic effect while searching for something else. These
discoveries commonly arise during laboratory experiments, animal studies, or early clinical trials.
Serendipitous discoveries can be broadly classified into the following categories:
1. Finding one thing while looking for another

7
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
Some of the most important breakthroughs in drug discovery have occurred when researchers
observed unexpected results while pursuing a different goal. A classic example is penicillin, discovered
by Alexander Fleming in 1928. Fleming was studying Staphylococcus bacteria, not searching for a new
drug, when he noticed that a contaminating mold, Penicillium notatum, inhibited bacterial growth.
This accidental observation led to the development of the first true antibiotic, revolutionizing
medicine. Similarly, William Henry Perkin’s synthesis of aniline purple in 1856 occurred while he was
attempting to prepare quinine. Although he did not achieve his original goal, the unexpected purple
dye launched the modern synthetic dye industry and laid the foundation for pharmaceutical
chemistry.
2. Success through a false rationale
In some cases, the original scientific hypothesis for developing a compound was incorrect, yet the
drug proved therapeutically valuable. For example:
• Potassium bromide was initially used in the 19th century for its presumed sedative effects
based on the idea that bromide ions could “calm the nervous system.” Despite the
oversimplified rationale, it became the first widely used antiepileptic agent.
• Chloral hydrate was synthesized as a potential sedative-hypnotic based on chemical intuition
rather than a clear understanding of brain physiology. It later became a reliable sedative for
insomnia and procedural sedation.
• Lithium: John Cade hypothesized in the 1940s that mania might be linked to a “toxic”
substance in urine counteracted by lithium salts. While the premise was incorrect, lithium
proved to have profound mood-stabilizing effects, revolutionizing the treatment of bipolar
disorder.
These examples illustrate that therapeutic success does not always require perfect scientific
reasoning; empirical observation and careful testing can uncover clinically valuable effects despite
flawed hypotheses.
3. Unintended indications (drug repurposing)
Sometimes a drug developed for one condition is later found useful for another. Sildenafil, initially
studied as an anti-anginal agent, was repurposed for erectile dysfunction due to unexpected clinical
effects. Other examples include minoxidil, originally an antihypertensive agent later used for hair
growth, and thalidomide, repurposed for multiple myeloma because of its immunomodulatory
properties.
4. Pure chance discoveries
Pure chance discoveries occur entirely by accident, without a deliberate hypothesis or target. The
therapeutic effect is recognized only after the observation. A classic example is lysergic acid
diethylamide (LSD), first synthesized by Albert Hofmann in 1938 while studying ergot alkaloids for
circulatory purposes. Its hallucinogenic effects were discovered unexpectedly when Hofmann
accidentally absorbed a small amount of the compound, highlighting the role of pure chance in
discovering biologically active compounds. Similarly, penicillin is also a pure chance discovery, as
Fleming was not searching for antibiotics at all.

Clinical Observations
Clinical observation refers to the identification of new drug leads based on unexpected therapeutic
effects or side-effects observed in human patients during clinical trials, routine medical practice, or
post-marketing surveillance. Most drugs exhibit multiple pharmacological actions; while one is
intended as the primary therapeutic effect, others are often considered side-effects. Occasionally,
these side-effects become the basis for new therapeutic indications.
Important examples of lead discovery through clinical observation include:

8
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
• Sulfonamides and diabetes: In 1942, a sulfathiazole derivative used for typhoid was observed
to cause profound hypoglycemia, leading to the development of oral hypoglycemic agents for
diabetes.
• Clonidine: Initially expected to act as a vasoconstrictor, its antihypertensive activity was
revealed during clinical trials.
• Sildenafil (Viagra): Its repositioning was driven by clinical side-effects observed during
cardiovascular trials.
• Trial-and-error in clinical practice: When standard therapies fail or cause adverse effects,
clinicians often modify doses or switch drugs. Such real-world adjustments generate valuable
observations that may inspire new lead identification or drug optimization.

Because clinical observations occur directly in humans, they provide early evidence of efficacy and
tolerability, although extensive follow-up studies are required to establish mechanism of action,
safety, and optimal dosing.

Significance and Limitations

Serendipitous discovery typically occurs in the laboratory or early experimental settings, whereas
clinical observation arises from human use and medical practice. Both approaches have historically
contributed to many important drugs and emphasize the importance of scientific alertness, clinical
experience, and open-minded inquiry.
However, these methods are unpredictable and cannot be planned systematically, limiting their use
as primary drug discovery strategies. Despite this limitation, they remain valuable complementary
approaches, especially for drug repurposing and the identification of novel therapeutic opportunities
that rational methods may overlook.

1.14. Lead Discovery Based on Drug Metabolism Studies

Lead discovery in drug development is often guided by understanding how compounds are
metabolized in the body. Drug metabolism studies help identify active metabolites, optimize
pharmacokinetic properties, and reduce toxicity, allowing researchers to select promising lead
9
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
compounds for further development. This approach is particularly useful when the parent compound
is inactive, weakly active, or toxic, but one or more of its metabolites exhibits therapeutic potential.

1. Role of Metabolites in Lead Discovery

o Many drugs are prodrugs, meaning the administered molecule is inactive or less
active, and its metabolite provides the therapeutic effect.
o Studying drug metabolism can reveal active or more potent metabolites that can be
developed as new lead compounds.
o Example: Codeine is metabolized to morphine, which provides most of its analgesic
effect. This insight can guide the development of other analgesic leads.
2. Types of Metabolic Modifications
Drug metabolism typically involves Phase I and Phase II reactions, which can affect lead
discovery:
o Phase I (functionalization): Oxidation, reduction, hydrolysis. May generate active,
inactive, or toxic metabolites.
▪ Example: Imipramine metabolized to desipramine, an active antidepressant
metabolite.
o Phase II (conjugation): Glucuronidation, sulfation, acetylation, methylation. These
usually increase water solubility and facilitate excretion, but sometimes produce
active metabolites.
3. Advantages of Metabolism-Guided Lead Discovery
o Identification of more potent or selective metabolites than the parent drug.
o Reduction of toxicity by avoiding harmful metabolic pathways.
o Optimization of pharmacokinetic properties, such as half-life and bioavailability.
o Rational prodrug design, converting poorly absorbed or unstable drugs into
metabolically active forms.
4. Examples of Metabolism-Based Lead Discovery
o Imipramine → Desipramine: Imipramine, an antidepressant, is metabolized to
desipramine, which has more selective noradrenergic activity and fewer side effects.
o Terfenadine → Fexofenadine: Terfenadine, an antihistamine, was metabolized in the
liver to fexofenadine, a safer metabolite that became a lead compound with reduced
cardiac toxicity.
o Codeine → Morphine: As mentioned, the analgesic effect of codeine is due to its
active metabolite morphine, guiding safer and more effective opioid development.
5. Application in Modern Drug Discovery
o High-throughput metabolite profiling can screen large chemical libraries for promising
active metabolites.
o In silico metabolism prediction helps anticipate metabolite activity and toxicity early
in the drug discovery process.
o Drugs with favorable metabolic profiles can serve as lead compounds for optimization
in structure–activity relationship (SAR) studies.

Drug metabolism studies provide a powerful strategy for lead discovery. By analyzing how compounds
are processed in the body, researchers can identify active metabolites, optimize pharmacokinetics,
reduce toxicity, and discover new therapeutic leads. This approach integrates pharmacology,
medicinal chemistry, and toxicology to streamline the early stages of drug development.

10
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
1.15. Rational Approaches to Lead Discovery

Rational lead discovery is the process of designing or selecting drug molecules based on knowledge of
biological targets (receptors, enzymes, or proteins) and their interactions with molecules, instead of
random screening. The goal is efficient development of drug candidates that are potent, selective,
safe, and clinically effective
1. Principles of Rational Lead Design
• Target Knowledge: Identify disease-related molecules or pathways.
• Lead Nucleus Selection: Use natural substrates, hormones, or endogenous molecules as
starting points.
o Example: Progesterone and estrogen → lead nuclei for oral contraceptives.
• Structural Optimization: Modify molecular groups to improve target binding and reduce side
effects.
o Example: Replacing N,N-diethyl amino with piperidino improves access to anionic
sites → major tranquilizers, local anesthetics.
• Rigidification: Reduces molecular flexibility, enhancing selectivity and potency and
influencing pharmacokinetics (pKa, lipophilicity).
2. Rational Drug Design (RDD)
• Definition: A drug design process that uses knowledge of targets and computational
methods to create molecules with optimal efficacy, selectivity, and safety.
• Methods:
1. Structure-Based Drug Design (SBDD)
2. Ligand-Based Design
3. De novo Design
4. Homology Modeling
• Advantages:
o Predicts drug-target interactions before synthesis.
o Reduces trial-and-error experimentation.
o Optimizes pharmacokinetics and reduces toxicity.
• Examples:
o Dorzolamide (1995): Carbonic anhydrase inhibitor designed using SBDD.

11
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
o Imatinib: Tyrosine kinase inhibitor targeting BCR-ABL in chronic myelogenous
leukemia.
3. Structure-Based Drug Design (SBDD)
• Definition: Uses the 3D structure of target proteins or enzymes to guide drug design.
• Process:
1. Identify the disease-relevant protein or enzyme.
2. Determine 3D structure via X-ray crystallography or NMR spectroscopy.
3. Analyze binding pockets and active sites.
4. Design molecules to fit precisely into these sites.
• Example:
o p53-MDM2 complex in cancer: Nutlin molecules designed to restore p53 function by
binding to hydrophobic pockets on MDM2.
4. Key Considerations in Rational Lead Discovery
• Druglikeness: Optimize absorption, distribution, metabolism, and excretion (ADME).
o Tool: Lipinski’s Rule of Five.
• Potency: Maximize binding to the target.
• Selectivity: Reduce off-target interactions to minimize side effects.
• Safety: Avoid toxic metabolites or interactions.
5. Summary Workflow
1. Target Identification: Disease-relevant receptors, enzymes, or proteins.
2. Lead Selection: Natural or endogenous molecules as starting points.
3. Molecular Design & Optimization: SAR studies, rigidification, modifying functional groups.
4. Structure-Based Design: Use 3D structures from X-ray or NMR.
5. Lead Development: Optimize for potency, selectivity, safety, and pharmacokinetics.

The figure illustrates the

rational discovery process of
Imatinib (Gleevec), a
targeted therapy for chronic
myelogenous leukemia
(CML). The workflow begins
with target identification,
where researchers
pinpointed the BCR-ABL
tyrosine kinase, produced by
the Philadelphia
chromosome, as the driver of
uncontrolled leukemia cell
proliferation. Next is lead
design, which involved
structure-based drug design
(SBDD) to create molecules that specifically inhibit the ATP-binding site of BCR-ABL, preventing
aberrant signaling. In the molecular optimization stage, the compounds were refined to enhance
selectivity, potency, oral bioavailability, and minimize toxicity, ensuring that the drug affects only
cancerous cells while sparing normal tissue. The final step produces the approved drug, Imatinib,
which is a selective BCR-ABL inhibitor, orally active, and well-tolerated, representing a landmark
example of rational, structure-guided lead discovery in modern pharmacology.

12
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
Section A: Multiple Choice Questions (MCQs)
1. A drug target is best defined as:
a) Any chemical compound causing a biological response
b) A biological entity involved in disease pathology
c) A therapeutic formulation
d) A clinical symptom
2. Which of the following is NOT a criterion for a good drug target?
a) Druggability
b) Clinical relevance
c) Commercial feasibility
d) High molecular weight
3. siRNA is mainly used in target validation to:
a) Activate gene expression
b) Silence specific mRNA
c) Enhance protein stability
d) Improve drug solubility
4. In the drug discovery pipeline, hit discovery follows:
a) Lead optimization
b) Preclinical studies
c) Target identification and validation
d) Clinical trials
5. A “hit” is best described as a compound that:
a) Is ready for clinical trials
b) Shows measurable activity against a target
c) Has optimal ADME properties
d) Is free from toxicity
6. The major limitation of random screening is:
a) High specificity
b) Hypothesis-driven nature
c) Low success rate
d) Target validation
7. High-throughput screening (HTS) primarily relies on:
a) Manual testing
b) Clinical observation
c) Automation and robotics
d) Ethnopharmacology
8. A Z′-factor value above _____ indicates a robust HTS assay.
a) 0.1
b) 0.2
c) 0.4
d) 0.9
9. Non-random screening is also known as:
a) Blind screening
b) Empirical screening
c) Target-based screening
d) Clinical screening
10. Artemisinin is an example of a lead discovered through:
a) Rational drug design
13
Department of Biotechnology
Brainware University, Kolkata
Programme Name and Semester: MASTER OF SCIENCE IN BIOTECHNOLOGY-2025
Course Name (Course Code): DRUG DESIGN (MBT20406A)
Class: MScBT-2025
Academic Session: 2025-2026 (EVEN)
b) Random screening
c) Ethnopharmacological approach
d) Drug metabolism studies
11. Sildenafil is a classic example of:
a) Prodrug design
b) Structure-based drug design
c) Serendipitous discovery
d) Random screening
12. Clinical observation-based lead discovery occurs mainly during:
a) In vitro assays
b) Animal studies
c) Human use and trials
d) Computational modeling
13. Codeine produces analgesic effects mainly due to:
a) Its parent compound
b) Phase II conjugation
c) Its active metabolite morphine
d) Enzyme inhibition
14. Phase I drug metabolism reactions mainly involve:
a) Conjugation
b) Functionalization
c) Elimination
d) Transport
15. Imatinib is a classic example of:
a) Random screening
b) Clinical observation
c) Structure-based rational drug design
d) Ethnomedicine

Section B: Short Answer Questions

1. Define target identification and explain its importance in drug discovery.
2. Differentiate between activity and potency with suitable examples.
3. Briefly explain the principle and advantages of High-Throughput Screening (HTS).
4. What is meant by ethnopharmacological approach to lead discovery? Mention two
examples.
5. How do drug metabolism studies contribute to lead identification?

Section C: Long Answer Questions

1. Describe the process of target validation. Discuss the genetic, biological, and chemical tools
used in this stage.
2. Explain the drug discovery pipeline from target identification to preclinical development,
highlighting the transition from hits to leads.
3. Discuss random screening and high-throughput screening (HTS) as methods of lead
discovery. Include advantages, limitations, and examples.
4. Elaborate on serendipitous discovery and clinical observations in drug discovery with
suitable historical and modern examples.
5. Describe the rational approaches to lead discovery, explaining structure-based drug design
and citing Imatinib as an example.
14
Department of Biotechnology
Brainware University, Kolkata